Biowaiver Courier Ma Gujarati Natak

Halki Diabetes Remedy

Diabetes Alternative Treatment

Get Instant Access

Abdul S, Poddar SS. A flexible technology for modified release of drugs: multi layered tablets. J Control

Release 2004; 97(3):393-405. Abrams J. Glyceryl trinitrate (nitroglycerin) and the organic nitrates. Choosing the method of administration. Drugs 1987; 34(3):391-403. Aldridge MA, Ito MK. Colesevelam hydrochloride: a novel bile acid-binding resin. Ann Pharmacother 2001; 35(7-8):898-907.

Atkins PJ. Dry powder inhalers: an overview. Respir Care 2005; 50(10):1304-12 (discussion 1312). Bach M, Lippold BC. Percutaneous penetration enhancement and its quantification. Eur J Pharm Biopharm 1998; 46(1):1-13.

Baker MT, Naguib M. Propofol: the challenges of formulation. Anesthesiology 2005; 103(4):860-76. Baldi F. Lansoprazole oro-dispersible tablet: pharmacokinetics and therapeutic use in acid-related disorders. Drugs 2005; 65(10):1419-26. Baldi F, Malfertheiner P. Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor. Digestion 2003; 67(1-2):1-5. Bang LM, Keating GM. Paroxetine controlled release. CNS Drugs 2004; 18(6):355-64 (discussion 365-6). Behar-Cohen F. Drug delivery systems to target the anterior segment of the eye: fundamental bases and clinical applications. J Fr Ophtalmol 2002; 25(5):537-44. Behrend M, Braun F. Enteric-coated mycophenolate sodium: tolerability profile compared with mycophe-

nolate mofetil. Drugs 2005; 65(8):1037-50. Bejan A, Turcu G. Liposomes: presentation and actual applicative trends in medicine. Rom J Intern Med 1995; 33(3-4):141-9.

Benninger MS. Amoxicillin/clavulanate potassium extended release tablets: a new antimicrobial for the treatment of acute bacterial sinusitis and community-acquired pneumonia. Expert Opin Pharmac-other 2003; 4(10):1839-46.

Bernkop-Schnurch A, Kast CE, Guggi D. Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systems. J Control Release 2003; 93(2):95-103. Bianchi PG, Parente F. Antacids for duodenal ulcer: current role. Antacids for duodenal ulcer: current role. Scand J Gastroenterol Suppl 1990; 174:48-53.

Bittner B, Mountfield RJ. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Curr Opin Drug Discov Devel 2002; 5(1):59-71.

Bourquin J, Schmidli H, van Hoogevest P, Leuenberger H. Basic concepts of artificial neural networks (ANN) modeling in the application to pharmaceutical development. Pharm Dev Technol 1997; 2(2):95-109.

Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001; 5(26):1-149.

Budde K, Glander P, Diekmann F, et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 2004; 5(6):1333-45.

Bunker M, Davies M, Roberts C. Towards screening of inhalation formulations: measuring interactions with atomic force microscopy. Expert Opin Drug Deliv 2005; 2(4):613-24.

Butcher EC. Can cell systems biology rescue drug discovery? Nat Rev Drug Discov 2005; 4(6):461-7.

Cabrera J, Redondo P, Becerra A, et al. Ultrasound-guided injection of polidocanol microfoam in the management of venous leg ulcers. Arch Dermatol 2004; 140(6):667-73.

Chang TM. Artificial cells with emphasis on bioencapsulation in biotechnology. Biotechnol Annu Rev 1995; 1:267-95.

Chaubal MV. Application of drug delivery technologies in lead candidate selection and optimization. Drug Discov Today 2004; 9(14):603-9.

Chen D, Maa YF, Haynes JR. Needle-free epidermal powder immunization. Expert Rev Vaccines 2002; 1(3):265-76.

Chew NY, Chan HK. The role of particle properties in pharmaceutical powder inhalation formulations. J Aerosol Med 2002; 15(3):325-30.

Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci 2003; 6(1):33-66.

Cleland JL. Protein delivery from biodegradable microspheres. Pharm Biotechnol 1997; 10:1-43.

Cole P. Pharmacologic and clinical comparison of cefaclor in immediate-release capsule and extended-release tablet forms. Clin Ther 1997; 19(4):617-25 (discussion 603).

Constantinides PP, Tustian A, Kessler DR. Tocol emulsions for drug solubilization and parenteral delivery. Adv Drug Deliv Rev 2004; 56(9):1243-55.

Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst 2002; 19(4-5):425-98.

Dahlof B, Andersson OK. A felodipine-metoprolol extended-release tablet: its properties and clinical development. J Hum Hypertens 1995; 9(Suppl. 2):S43-7.

Dando TM, Scott LJ. Abacavir plus lamivudine: a review of their combined use in the management of HIV infection. Drugs 2005; 65(2):285-302.

Darkes MJ, Perry CM. Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections. Am J Respir Med 2003; 2(2):175-201.

Davis SS. Coming of age of lipid-based drug delivery systems. Adv Drug Deliv Rev 2004; 56(9):1241-2.

Davis SS, Illum L. Absorption enhancers for nasal drug delivery. Clin Pharmacokinet 2003; 42(13):1107-28.

De Moor R, Verbeeck R, Martens L. Evaluation of long-term release of fluoride by type II glass ionomer cements with a conventional hardening reaction. Rev Belge Med Dent 1996; 51(3):22-35.

Dempski RE, Scholtz EC, Oberholtzer ER, Yeh KC. Pharmaceutical design and development of a Sinemet controlled-release formulation. Neurology 1989; 39(11 Suppl. 2):20-4.

Devlin JW, Welage LS, Olsen KM. Proton pump inhibitor formulary considerations in the acutely ill. Part 1: pharmacology, pharmacodynamics, and available formulations. Ann Pharmacother 2005; 39(10):1667-77 (Epub 2005 August 23).

Dhaon NA. Amoxicillin tablets for oral suspension in the treatment of acute otitis media: a new formulation with improved convenience. Adv Ther 2004; 21(2):87-95.

Digenis GA, Gold TB, Shah VP. Cross-linking of gelatin capsules and its relevance to their in vitro-in vivo performance. J Pharm Sci 1994; 83(7):915-21.

Doelker E. Recent advances in tableting science. Boll Chim Farm 1988; 127(2):37-49.

Doelker E, Massuelle D. Benefits of die-wall instrumentation for research and development in tabletting. Eur J Pharm Biopharm 2004; 58(2):427-44.

Dowson AJ, Almqvist P. Part III: the convenience of, and patient preference for, zolmitriptan orally disintegrating tablet. Curr Med Res Opin 2005; 21(Suppl. 3):S13-17.

Duchene D, Ponchel G. Principle and investigation of the bioadhesion mechanism of solid dosage forms. Biomaterials 1992; 13(10):709-14.

DuPont HL. Nonfluid therapy and selected chemoprophylaxis of acute diarrhea. Am J Med 1985; 78(6B):81-90.

DuPont HL. Bismuth subsalicylate in the treatment and prevention of diarrheal disease. Drug Intell Clin Pharm 1987; 21(9):687-93.

Faassen F, Vromans H. Biowaivers for oral immediate-release products: implications of linear pharmacokinetics. Clin Pharmacokinet 2004; 43(15):1117-26.

Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliv Rev 2005; 57(2):303-16.

Felt O, Buri P, Gurny R. Chitosan: a unique polysaccharide for drug delivery. Drug Dev Ind Pharm 1998; 24(11):979-93.

Femia RA, Goyette RE. The science of megestrol acetate delivery: potential to improve outcomes in cachexia. BioDrugs 2005; 19(3):179-87.

Figgitt DP, Plosker GL. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection. Drugs 2000; 60(2):481-516.

Flores NA. Ezetimibe + simvastatin (Merck/Schering-Plough). Curr Opin Investig Drugs 2004; 5(9):984-92.

Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2004; 1(1):67-86.

Frishman WH, Sherman D, Feinfeld DA. Innovative drug delivery systems in cardiovascular medicine: nifedipine-GITS and clonidine-TTS. Cardiol Clin 1987; 5(4):703-16.

Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carrier Syst 2004; 21(6):433-76.

Fuseau E, Petricoul O, Moore KH, Barrow A, Ibbotson T. Clinical pharmacokinetics of intranasal sumatriptan. Clin Pharmacokinet 2002; 41(11):801-11.

Gallen CC. Strategic challenges in neurotherapeutic pharmaceutical development. NeuroRx 2004; 1(1):165-80.

Garg S, Kandarapu R, Vermani K, et al. Development pharmaceutics of microbicide formulations. Part I: preformulation considerations and challenges. AIDS Patient Care STDS 2003; 17(1):17-32.

Garg S, Tambwekar KR, Vermani K, et al. Development pharmaceutics of microbicide formulations. Part II: formulation, evaluation, and challenges. AIDS Patient Care STDS 2003; 17(8):377-99.

Gehl J. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand 2003; 177(4):437-47.

Gill J, Feinberg J. Saquinavir soft gelatin capsule: a comparative safety. Drug Saf 2001; 24(3):223-32.

Gillis JC, Benfield P, Goa KL. Transnasal butorphanol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management. Drugs 1995; 50(1):157-75.

Goldenberg MM. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Clin Ther 1999; 21(4):634-42.

Goldenheim PD, Conrad EA, Schein LK. Treatment of asthma by a controlled-release theophylline tablet formulation: a review of the North American experience with nocturnal dosing. Chronobiol Int 1987; 4(3):397-408.

Goldstein JL, Larson LR, Yamashita BD. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy: clinical and economic implications of a single-tablet formulation of diclofenac/miso-prostol. Am J Manage Care 1998; 4(5):687-97.

Gooding OW. Process optimization using combinatorial design principles: parallel synthesis and design of experiment methods. Curr Opin Chem Biol 2004; 8(3):297-304.

Goodnow RA, Jr. Current practices in generation of small molecule new leads. J Cell Biochem Suppl 2001; (Suppl. 37) 13-21.

Gotfried MH. Clarithromycin (Biaxin) extended-release tablet: a therapeutic. Expert Rev Anti Infect Ther 2003; 1(1):9-20.

Gregoriadis G. Liposomes as a drug delivery system: optimization studies. Adv Exp Med Biol 1988; 238:151-9 (No abstract available).

Grosdidier J, Boissel P, Bresler L, Vidrequin A. Stenosing and perforated ulcers of the small intestine related to potassium chloride in enteric-coated tablets. Apropos of 11 cases. Chirurgie 1989; 115(3):163-9 (French).

Grzeszczak W. Cardura XL—a unique drug formulation—doxazosine administered in a slow-release form (doxazosine GITS). Przegl Lek 2000; 57(11):643-54.

Gudgin Dickson EF, Goyan RL, Pottier RH. New directions in photodynamic therapy. Cell Mol Biol (Noisy-le-grand) 2002; 48(8):939-54.

Guyton JR. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 2004; 5(6):1385-98.

Hadgraft J. Passive enhancement strategies in topical and transdermal drug delivery. Int J Pharm 1999; 184(1):1-6.

Haefner S, Knietsch A, Scholten E, Braun J, Lohscheidt M, Zelder O. Biotechnological production and applications of phytases. Appl Microbiol Biotechnol 2005; 68(5):588-97 (Epub 2005 October 26).

Harashima H, Shinohara Y, Kiwada H. Intracellular control of gene trafficking using liposomes as drug carriers. Eur J Pharm Sci 2001; 13(1):85-9.

Harashima H, Ishida T, Kamiya H, Kiwada H. Pharmacokinetics of targeting with liposomes. Crit Rev Ther Drug Carrier Syst 2002; 19(3):235-75.

Hardy IJ, Fitzpatrick S, Booth SW. Rational design of powder formulations for tamp filling processes. J Pharm Pharmacol 2003; 55(12):1593-9.

Harsch IA. Inhaled insulins: their potential in the treatment of diabetes mellitus. Treat Endocrinol 2005; 4(3):131-8.

Hatefi A, Amsden B. Camptothecin delivery methods. Pharm Res 2002; 19(10):1389-99.

Hausheer FH, Kochat H, Parker AR, et al. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent. Cancer Chemother Pharmacol 2003; 52(Suppl. 1):S3-15 (Epub 2003 June 18).

Heinig R. Clinical pharmacokinetics of nisoldipine coat-core. Clin Pharmacokinet 1998; 35(3):191-208 (Erratum in: Clin Pharmacokinet 1998 November; 35(5):390).

Hiestand EN. Mechanical properties of compacts and particles that control tableting success. J Pharm Sci 1997; 86(9):985-90.

Hirata K, Iwanami H. The role of triptans and analgesics for primary headache treatment. Nippon Rinsho 2005; 63(10):1797-801 (Japanese).

Hirschberger R. Pharmacokinetics and -dynamics of retard formation of isradipine. Summary of studies. Fortschr Med 1993; 111(30):481-4.

Huang Y, Leobandung W, Foss A, Peppas NA. Molecular aspects of muco- and bioadhesion: tethered structures and site-specific surfaces. J Control Rel 2000; 65(1-2):63-71.

Itkin YM, Trujillo TC. Intravenous immunoglobulin-associated acute renal failure: case series and literature. Pharmacotherapy 2005; 25(6):886-92.

Jones DH, Partidos CD, Steward MW, Farrar GH. Oral delivery of poly(lactide-co-glycolide) encapsulated vaccines. Behring Inst Mitt 1997;(98):220-8.

Jovanovic N, Bouchard A, Hofland GW, Witkamp GJ, Crommelin DJ, Jiskoot W. Stabilization of proteins in dry powder formulations using supercritical fluid technology. Pharm Res 2004; 21(11):1955-69.

Kalia YN, Guy RH. Modeling transdermal drug release. Adv Drug Deliv Rev 2001; 48(2-3):159-72.

Kanjickal DG, Lopina ST. Modeling of drug release from polymeric delivery systems—a review. Crit Rev Ther Drug Carrier Syst 2004; 21(5):345-86.

Karlsson L, Torstensson A, Taylor LT. The use of supercritical fluid extraction for sample preparation of pharmaceutical formulations. J Pharm Biomed Anal 1997; 15(5):601-11.

Kaur IP, Kanwar M. Ocular preparations: the formulation approach. Drug Dev Ind Pharm 2002; 28(5):473-93.

Kleinebudde P. Roll compaction/dry granulation: pharmaceutical applications. Eur J Pharm Biopharm 2004; 58(2):317-26.

Knop K. Active ingredient release from solid drug forms—test methods, evaluation, influencing parameters. Pharm Unserer Zeit 1999; 28(6):301-8 (German).

Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin Ther 2004; 26(12):1994-2002.

Kostarelos K. Rational design and engineering of delivery systems for therapeutics: biomedical exercises in colloid and surface science. Adv Colloid Interface Sci 2003; 106:147-68.

Kozubek A, Gubernator J, Przeworska E, Stasiuk M. Liposomal drug delivery, a novel approach: PLARosomes. Acta Biochim Pol 2000; 47(3):639-49.

Kuhlmann J. Alternative strategies in drug development: clinical pharmacological aspects. Int J Clin Pharmacol Ther 1999; 37(12):575-83.

Kulkarni SB, Betageri GV, Singh M. Factors affecting microencapsulation of drugs in liposomes. J Microencapsul 1995; 12(3):229-46.

Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003; 56(6):600-12.

Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 2005; 50(9):1161-76.

Leuenberger H. New trends in the production of pharmaceutical granules: batch versus continuous processing. Eur J Pharm Biopharm 2001; 52(3):289-96.

Levy RA. Therapeutic inequivalence of pharmaceutical alternates. Am Pharm 1985; NS25(4):28-39.

Lightman S. Somatuline Autogel: an extended release lanreotide formulation. Hosp Med 2002; 63(3):162-5.

Maa YF, Prestrelski SJ. Biopharmaceutical powders: particle formation and formulation considerations. Curr Pharm Biotechnol 2000; 1(3):283-302.

Machida Y. Development of topical drug delivery systems utilizing polymeric materials. Yakugaku Zasshi 1993; 113(5):356-68 (Japanese).

Mainardes RM, Silva LP. Drug delivery systems: past, present, and future. Curr Drug Targets 2004; 5(5):449-55.

Man M, Rugo H. Paclitaxel poliglumex. Cell Therapeutics/Chugai Pharmaceutical. IDrugs 2005; 8(9):739-54.

Maroni A, Zema L, Cerea M, Sangalli ME. Oral pulsatile drug delivery systems. Expert Opin Drug Deliv 2005; 2(5):855-71.

McKay B, Hoogenraad M, Damen EW, Smith AA. Advances in multivariate analysis in pharmaceutical process development. Curr Opin Drug Discov Devel 2003; 6(6):966-77.

Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001; 47(2-3):165-96.

Melia CD, Davis SS. Review article: mechanisms of drug release from tablets and capsules. 2. Dissolution. Aliment Pharmacol Ther 1989; 3(6):513-25.

Michele TM, Knorr B, Vadas EB, Reiss TF. Safety of chewable tablets for children. J Asthma 2002; 39(5):391-403.

Mooradian AD. Towards single-tablet therapy for type 2 diabetes mellitus. Rationale and recent developments. Treat Endocrinol 2004; 3(5):279-87.

Moribe K, Maruyama K. Pharmaceutical design of the liposomal antimicrobial agents for infectious disease. Curr Pharm Des 2002; 8(6):441-54.

Morissette SL, Almarsson O, Peterson ML, et al. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv Drug Deliv Rev 2004; 56(3):275-300.

Nagai T. New drug development by innovative drug administration—"change" in pharmaceutical field. Yakugaku Zasshi 1997; 117(10-11):963-71.

Nail SL, Jiang S, Chongprasert S, Knopp SA. Fundamentals of freeze-drying. Pharm Biotechnol 2002; 14:281-360.

Najib J. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation. Clin Ther 2002; 24(12):2022-50.

Nishida K. Development of drug delivery system based on a new administration route for targeting to the specific region in the liver. Yakugaku Zasshi 2003; 123(8):681-9 (Japanese).

Norman TR, Olver JS. New formulations of existing antidepressants: advantages in the management of depression. CNS Drugs 2004; 18(8):505-20.

Nuijen B, Bouma M, Schellens JH, Beijnen JH. Progress in the development of alternative pharmaceutical formulations of taxanes. Invest New Drugs 2001; 19(2):143-53.

Nunn T, Williams J. Formulation of medicines for children. Br J Clin Pharmacol 2005; 59(6):674-6.

Odegard PS, Capoccia KL. Inhaled insulin: Exubera. Ann Pharmacother 2005; 39(5):843-53 (Epub 2005 April 12).

O'Hagan DT, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines 2003; 2(2):269-83.

Okada N. Design and creation of cytomedicine for application to cell therapy. Yakugaku Zasshi 2005; 125(8):601-15 (Japanese).

Ormrod D, Goa KL. Intranasal metoclopramide. Drugs 1999; 58(2):315-22 (discussion 323-4).

Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabet Med 2003; 20(11):886-98.

Panchagnula R, Agrawal S, Ashokraj Y, Varma M, Sateesh K, Bhardwaj V, Bedi S, Gulati I, Parmar J, Kaul CL, et al. Fixed dose combinations for tuberculosis: lessons learned from clinical, formulation and regulatory perspective. Methods Find Exp Clin Pharmacol 2004; 26(9):703-21.

Pathak P, Meziani MJ, Sun YP. Supercritical fluid technology for enhanced drug delivery. Expert Opin Drug Deliv 2005; 2(4):747-61.

Patro SY, Freund E, Chang BS. Protein formulation and fill-finish operations. Biotechnol Annu Rev 2002; 8:55-84.

Pawar R, Ben-Ari A, Domb AJ. Protein and peptide parenteral controlled delivery. Expert Opin Biol Ther 2004; 4(8):1203-12.

Perkins AC, Frier M. Nuclear medicine techniques in the evaluation of pharmaceutical formulations. Pharm World Sci 1996; 18(3):97-104.

Perkins AC, Frier M. Radionuclide imaging in drug development. Curr Pharm Des 2004; 10(24):2907-21.

Pettipher R, Cardon LR. The application of genetics to the discovery of better medicines. Pharmacoge-nomics 2002; 3(2):257-63.

Pfister WR, Hsieh DS. Permeation enhancers compatible with transdermal drug delivery systems. Part I: selection and formulation considerations. Med Device Technol 1990; 1(5):48-55 (Erratum in: Med Device Technol 1990-November-December; 1(6):33).

Pfister WR, Hsieh DS. Permeation enhancers compatible with transdermal drug delivery systems: part II: system design considerations. Med Device Technol 1990; 1(6):28-33.

Rabiskova M, Vostalova L, Medvecka G, Horackova D. Hydrophilic gel matrix tablets for oral administration of drugs. Ceska Slov Farm 2003; 52(5):211-7 (Czech).

Ram CV, Featherston WE. Calcium antagonists in the treatment of hypertension. An overview. Chest 1988; 93(6):1251-3.

Ramsay EC, Dos Santos N, Dragowska WH, Laskin JJ, Bally MB. The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. Curr Drug Deliv 2005; 2(4):341-51.

Ranade VV. Drug delivery systems 5B. Oral drug delivery. J Clin Pharmacol 1991; 31(2):98-115.

Reddy KR. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother 2000; 34(7-8):915-23.

Reeves RR, Wallace KD, Rogers-Jones C. Orally disintegrating olanzapine: a possible alternative to injection of antipsychotic drugs. J Psychosoc Nurs Ment Health Serv 2004; 42(5):44-8.

Richard A, Margaritis A. Poly(glutamic acid) for biomedical applications. Crit Rev Biotechnol 2001; 21(4):219-32.

Ritschel WA. Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral. Clin Transplant 1996; 10(4):364-73.

Sable D, Murakawa gJ. Quinolones in dermatology. Dis Mon 2004; 50(7):381-94.

Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discov Today 2005; 10(2):139-47.

Schmidt PC, Christin I. Effervescent tablets—a nearly forgotten drug form. Pharmazie 1990; 45(2):89-101.

Schneider G, Fechner U. Computer-based de novo design of drug-like molecules. Nat Rev Drug Discov 2005; 4(8):649-63.

Schumacher HR, Jr. Ketoprofen extended-release capsules: a new formulation for the treatment of osteoarthritis and rheumatoid arthritis. Clin Ther 1994; 16(2):145-59.

Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 1998; 50(4):375-82.

Sezaki H. Drug delivery systems. Gan To Kagaku Ryoho 1985; 12(11):2077-82.

Sharma VK. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole. Am J Health Syst Pharm 1999; 56(23 Suppl. 4):S18-21 (Erratum in: Am J Health Syst Pharm 2000 April 1; 57(7):699).

Sharpe M, Ormrod D, Jarvis B. Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels. Am J Cardiovasc Drugs 2002; 2(2):125-32 (discussion 133-4).

Shigeyama M. Preparation of a gel-forming ointment base applicable to the recovery stage of bedsore and clinical evaluation of a treatment method with different ointment bases suitable to each stage of bedsore. Yakugaku Zasshi 2004; 124(2):55-67 (Japanese).

Siepmann J, Gopferich A. Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv Drug Deliv Rev 2001; 48(2-3):229-47.

Singh B, Kumar R, Ahuja N. Optimizing drug delivery systems using systematic "design of experiments." Part I: fundamental aspects. Crit Rev Ther Drug Carrier Syst 2005; 22(1):27-105.

Singh B, Dahiya M, Saharan V, Ahuja N. Optimizing drug delivery systems using systematic "design of experiments." Part II: retrospect and prospects. Crit Rev Ther Drug Carrier Syst 2005; 22(3):215-94.

Singla AK, Chawla M. Chitosan: some pharmaceutical and biological aspects—an update. J Pharm Pharmacol 2001; 53(8):1047-67.

Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002; 235(1-2):179-92.

Sinha VR, Kumria R. Microbially triggered drug delivery to the colon. Eur J Pharm Sci 2003; 18(1):3-18.

Smart JD. Buccal drug delivery. Expert Opin Drug Deliv 2005; 2(3):507-17.

Song H, Guo T, Zhang R, et al. Preparation of the traditional Chinese medicine compound recipe heart-protecting musk pH-dependent gradient-release pellets. Drug Dev Ind Pharm 2002; 28(10):1261-73.

Speiser PP. Nanoparticles and liposomes: a state of the art. Methods Find Exp Clin Pharmacol 1991; 13(5):337-42.

Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004; 21(2):201-30.

Sun Y, Peng Y, Chen Y, Shukla AJ. Application of artificial neural networks in the design of controlled release drug delivery systems. Adv Drug Deliv Rev 2003; 55(9):1201-15.

Swainston HT, Keating GM. Extended-release carbamazepine capsules: in bipolar I disorder. CNS Drugs 2005; 19(8):709-16.

Takada S, Ogawa Y. Design and development of controlled release of drugs from injectable microcapsules. Nippon Rinsho 1998; 56(3):675-9.

Takakura Y, Nishikawa M, Yamashita F, Hashida M. Influence of physicochemical properties on pharmacokinetics of non-viral vectors for gene delivery. J Drug Target 2002; 10(2):99-104.

Takayama K, Fujikawa M, Nagai T. Artificial neural network as a novel method to optimize pharmaceutical formulations. Pharm Res 1999; 16(1):1-6.

Takayama K, Fujikawa M, Obata Y, Morishita M. Neural network based optimization of drug formulations. Adv Drug Deliv Rev 2003; 55(9):1217-31.

Takeuchi H, Thongborisute J, Matsui Y, Sugihara H, Yamamoto H, Kawashima Y. Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems. Adv Drug Deliv Rev 2005; 57(11):1583-94 (Epub 2005 September 16).

Tobyn M, Staniforth JN, Morton D, Harmer Q, Newton ME. Active and intelligent inhaler device development. Int J Pharm 2004; 277(1-2):31-7.

Todd PA, Faulds D. Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs 1992; 44(2):251-77.

Toguchi H, Ogawa Y, Okada H, Yamamoto M. Once-a-month injectable microcapsules of leuprorelin acetate. Yakugaku Zasshi 1991; 111(8):397-409.

Turker S, Onur E, Ozer Y. Nasal route and drug delivery systems. Pharm World Sci 2004; 26(3):137-42.

Tye H. Application of statistical 'design of experiments' methods in drug discovery. Drug Discov Today 2004; 9(11):485-91.

Valenta C, Auner BG. The use of polymers for dermal and transdermal delivery. Eur J Pharm Biopharm 2004; 58(2):279-89.

Wagstaff AJ, Goa KL. Once-weekly fluoxetine. Drugs 2001; 61(15):2221-8 (discussion 2229-30).

Wagstaff AJ, Figgitt DP. Extended-release metformin hydrochloride. Single-composition osmotic tablet formulation. Treat Endocrinol 2004; 3(5):327-32.

Wassef NM, Alving CR, Richards RL. Liposomes as carriers for vaccines. Immunomethods 1994; 4(3):217-22.

Wellington K. Rosiglitazone/Metformin. Drugs 2005; 65(11):1581-92 (discussion 1593-4).

Wernsdorfer WH. Coartemether (artemether and lumefantrine): an oral antimalarial drug. Expert Rev Anti Infect Ther 2004; 2(2):181-96.

White NS, Errington RJ. Fluorescence techniques for drug delivery research: theory and practice. Adv Drug Deliv Rev 2005; 57(1):17-42.

Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 2001; 26(3):159-69.

Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004; 56(9):1257-72.

Wouters J, Ooms F. Small molecule crystallography in drug design. Curr Pharm Des 2001; 7(7):529-45.

Yalkowsky SH, Krzyzaniak JF, Ward GH. Formulation-related problems associated with intravenous drug delivery. J Pharm Sci 1998; 87(7):787-96.

Yeo Y, Park K. Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch Pharm Res 2004; 27(1):1-12.

Yilmaz E, Borchert HH. Effect of lipid-containing, positively charged nanoemulsions on skin hydration, elasticity and erythema—an in vivo study. Int J Pharm 2006; 307(2):232-8 (Epub 2005 November 11).

Young SS, Lam RL, Welch WJ. Initial compound selection for sequential screening. Curr Opin Drug Discov Devel 2002; 5(3):422-7.

Zargar A, Basit A, Mahtab H. Sulphonylureas in the management of type 2 diabetes during the fasting month of Ramadan. J Indian Med Assoc 2005; 103(8):444-6.

Zhang GG, Law D, Schmitt EA, Qiu Y. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv Drug Deliv Rev 2004; 56(3):371-90.

Zimmermann U, Mimietz S, Zimmermann H, et al. Hydrogel-based non-autologous cell and tissue therapy. Biotechniques 2000; 29(3):564-72 (574, 576 passim).

Was this article helpful?

0 0
Dealing With Asthma Naturally

Dealing With Asthma Naturally

Do You Suffer From ASTHMA Chronic asthma is a paralyzing, suffocating and socially isolating condition that can cause anxiety that can trigger even more attacks. Before you know it you are caught in a vicious cycle Put an end to the dependence on inhalers, buying expensive prescription drugs and avoidance of allergenic situations and animals. Get control of your life again and Deal With Asthma Naturally

Get My Free Ebook

Post a comment